DDInter380 DDInter1658
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cimetidine {u} (Compound) treats {v} (Disease) obesity
Cimetidine {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Cimetidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Cimetidine {u} (Compound) downregulates {v} (Gene) COTL1
Cimetidine {u} (Compound) causes {v} (Side Effect) Flatulence
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quinestrol
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indomethacin
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Labetalol
Cimetidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Cimetidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Cimetidine (Compound) treats obesity (Disease)
Cimetidine (Compound) binds CYP3A7-CYP3A51P (Gene)
Cimetidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Cimetidine (Compound) downregulates COTL1 (Gene)
Cimetidine (Compound) causes Flatulence (Side Effect)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Indomethacin
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib